Neuroimaging-AI Endophenotypes of Brain Diseases in the General Population: Towards a Dimensional System of Vulnerability

Junhao Wen[1*], Ioanna Skampardoni[2], Ye Ella Tian[3], Zhijian Yang[2], Yuhan Cui[2], Guray Erus[2], Gyujoon Hwang[2], Erdem Varol[4], Aleix Boquet-Pujadas[5], Ganesh B. Chand[6], Ilya Nasrallah[2], Theodore Satterthwaite[7], Haochang Shou[2], Li Shen[8], Arthur W. Toga[9], Andrew Zaleskey[3], Christos Davatzikos[2,*]

[1]Laboratory of AI and Biomedical Science (LABS), Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, California, USA
[2]Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated Diagnostics (AI^{2}D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
[3]Melbourne Neuropsychiatry Centre, Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia
[4]Department of Computer Science and Engineering, New York University, New York, USA
[5]Biomedical Imaging Group, EPFL, Lausanne, Switzerland
[6]Department of Radiology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA
[7]Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
[8]Department of Biostatistics, Epidemiology and Informatics University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
[9]Laboratory of Neuro Imaging (LONI), Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, California, USA

*Corresponding authors:
Junhao Wen, junhaowe@usc.edu
2025 Zonal Ave, Los Angeles, CA 90033, United States
Christos Davatzikos, christos.davatzikos@pennmedicine.upenn.edu
3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States

Word counts: 5669 words

Abstract

Disease heterogeneity poses a significant challenge for precision diagnostics in both clinical and sub-clinical stages. Recent work leveraging artificial intelligence (AI) has offered promise to dissect this heterogeneity by identifying complex intermediate phenotypes – herein called dimensional neuroimaging endophenotypes (DNEs) – which subtype various neurologic and neuropsychiatric diseases. We investigate the presence of nine such DNEs derived from independent yet harmonized studies on Alzheimer's disease (AD1-2)[1], autism spectrum disorder (ASD1-3)[2], late-life depression (LLD1-2)[3], and schizophrenia (SCZ1-2)[4], in the general population of 39,178 participants in the UK Biobank study. Phenome-wide associations revealed prominent associations between the nine DNEs and phenotypes related to the brain and other human organ systems. This phenotypic landscape aligns with the SNP-phenotype genome-wide associations, revealing 31 genomic loci associated with the nine DNEs (Bonferroni corrected P-value $< 5\times10^{-8}/9$). The DNEs exhibited significant genetic correlations, colocalization, and causal relationships with multiple human organ systems and chronic diseases. A causal effect (odds ratio=1.25 [1.11, 1.40], P-value=8.72×10^{-4}) was established from AD2, characterized by focal medial temporal lobe atrophy, to AD. The nine DNEs and their polygenic risk scores significantly improved the prediction accuracy for 14 systemic disease categories and mortality. These findings underscore the potential of the nine DNEs to identify individuals at a high risk of developing the four brain diseases during preclinical stages for precision diagnostics. All results are publicly available at: http://labs.loni.usc.edu/medicine/.

Main

Disease heterogeneity[2,3,5–10] has been a significant challenge for precision medicine[11], including precision neuroscience. A new era powered by artificial intelligence (AI) and large-scale, multi-omics biomarkers may enable us to quantify individualized liability for various brain diseases[12,13]. Recent work has leveraged semi-supervised clustering methods (**Fig. 1a** and **Supplementary eMethod 1**) to tackle this challenge. These methods characterize the disease heterogeneity by constructing a mapping or transformation from a reference group (e.g., healthy controls) to a target group (i.e., patients with a specific disease). In clinical neuroscience, these methods can quantify deviation from typical brain structure measured by T1-weighted magnetic resonance imaging (MRI)[1–4]. They represent disease-related neuroanatomical heterogeneity via k low-dimensional categorical subtypes associated with specific patterns of brain change relative to the reference group. Instead of focusing on the k categorical subtypes, we investigated their corresponding continuous phenotypes[14], given that brain diseases develop along a continuous spectrum. Each neuroanatomical pattern's level of expression, therefore, serves as a dimensional AI-derived biomarker pertinent to the respective disease.

Previous heterogeneity research has primarily focused on within-disease heterogeneity[2,3,5–10]. However, this approach neglects the shared etiology, genetics, and clinical manifestations among different brain diseases. Conversely, while several studies have investigated the shared genetic components across various brain diseases, they have overlooked the important aspect of disease heterogeneity within each condition[15,16]. As such, a broad perspective is required to simultaneously investigate disease heterogeneity, spanning multiple neurodegenerative and neuropsychiatric disorders. This holistic approach aids in understanding the commonalities and interrelationships between these brain diseases and multi-organ systems of the human[17,18]. Such an effort could simultaneously capture neurobiological heterogeneity within disorders and explain shared features, mechanisms, and risk factors across disorders. Ultimately, unraveling neurobiological heterogeneity within neuropsychiatric syndromes and explaining co-morbidity among them promises to accelerate more effective diagnosis, treatment, and prevention strategies.

Recent work leveraging AI-derived biomarkers identified using semi-supervised learning has offered novel ways to capture complex neuroanatomical heterogeneity within disease populations[2,3,5–9]. However, whether these biomarkers are present in the general population, potentially simultaneously, remains unknown. Here, we sought to measure the presence of multiple AI-based signatures in the general population, delineate common mechanisms among them, and shed light on their relationship with numerous human organ systems[17,18]. To do this, we capitalized on nine imaging biomarkers recently derived from regional gray matter (GM) volumetrics derived from several large-scale disease-focused consortia, including ADNI[19] for Alzheimer's disease (AD1-2), ABIDE[20] for autism spectrum disorder (ASD1-3), LLD[3] for late-life depression older than 65 years old (LLD1-2), and PHENOM[4] for schizophrenia (SCZ1-2). We first conceptualized these biomarkers as the dimensional neuroimaging endophenotype (DNE), seeking to test the endophenotype hypothesis in psychiatry[21–23], which suggests that such measurable intermediate biomarkers (i.e., the endophenotypes) serve as intermediate phenotypes between genetics and clinical symptoms of the disease. They are thought to be more closely related to the underlying etiology (or genetics) than the complex clinical symptoms or the disease itself.

In this study, we evaluated the manifestation of the nine DNEs in the general population using the extensive and comprehensive multi-omics data available in the UK Biobank study[24]

(UKBB, **Method 1**), collected from more than 500,000 participants in the United Kingdom. The
pre-trained AI models (**Method 2**) from the four disease populations were applied to the 39,178
participants with brain MRI[25] and genetic[26] data from the UKBB general population. To
delineate the phenotypic landscape of the nine DNEs, we first tested whether the
neuroanatomical patterns of the nine DNEs are present in the UKBB general population.
Subsequently, we conducted a phenome-wide association study (PWAS, **Method 3**) to establish
associations between the nine DNEs and additional 611 UKBB phenotypes, including brain
imaging-derived phenotypes (IDPs), traits related to multiple human organ systems, cognition,
and lifestyle factors. To depict their genetic architecture, we performed a genome-wide
association study (GWAS, **Method 4**) linking the nine DNEs to 6,477,810 quality-checked
common single nucleotide polymorphisms (SNPs). Furthermore, we conducted analyses to
investigate genetic correlations, colocalization, and causal relationships between the nine DNEs,
nine human organ systems, and several chronic diseases. Finally, we assessed the ability of the
nine DNEs and their corresponding PRSs to predict 14 systemic disease categories and mortality
(**Method 5**).
112

113 **Results**

114 Our analytic framework involves computational genomics, statistical methods, and machine
115 learning to elucidate the phenotypic landscape and genetic architecture of the nine DNEs, as
116 illustrated in **Fig. 1**.
117

118 **Figure 1**: **Study workflow**

119
a) The concept of semi-supervised learning methods used in this study (**Method 1**). These AI
methods model the patterns and transformations from the healthy control (CN) to the patient
(PT) domain, thus capturing variations related to underlying disease pathology. Nine DNEs
previously published[1–4] from four disease-focused, case-control studies were investigated,
including ADNI[19] for Alzheimer's disease (AD1-2), ABIDE[20] for autism spectrum disorder
(ASD1-3), LLD[3] for late-life depression older than 65 years old (LLD1-2), and PHENOM[4] for
schizophrenia (SCZ1-2). **b**) The expression of the nine DNEs in the UK Biobank (UKBB)
general population. The trained models were then applied to the UKBB population to quantify
the expression of the neuroanatomical patterns of the nine DNEs at individual levels; a higher

DNE score indicates a greater expression (manifestation/presence) of the respective
neuroanatomical pattern. For example, the blue samples express predominantly AD2, whereas
the pink sample express predominantly SCZ2. The kernel density estimate for each DNE is
shown. **c**) Phenome- and genome-wide analyses performed in this study for the nine DENs.
phenome-wide association studies (PWAS) were conducted to associate the nine DNEs with
phenotypes across nine organ systems, cognition, and lifestyle factors. Genome-wide association
studies (GWAS) were performed to investigate associations between the nine DNEs and
common genetic variants (SNPs). Finally, the nine DNEs and their polygenic risk scores
predicted 14 disease categories (ICD-10-based) and mortality.
138
All nine DNEs are evident in the general population

We tested whether the neuroanatomical patterns defined in the four disease populations could be
found in the general population. We applied the DNE models pre-trained for each disease
population to the UKBB general population to measure the degree of expression of each DNE at
the individual level.
We first summarize the neuroanatomical patterns of the nine DNEs (**Fig. 2a** and **Method
3b**). The original patterns identified in the disease populations[1–4] manifest in the general
population. AD1 exhibits a pattern of brain atrophy (i.e., negative correlation) across various
brain volumes, while AD2 involves focal atrophy of the medial temporal lobe and hippocampus.
ASD1 captures a pattern of mildly lower GM volumes in several subcortical regions, including
the pallidum, amygdala, and putamen, whereas ASD2 reflects a pattern of relatively larger GM
volumes (i.e., positive correlation) in subcortical regions. ASD3, conversely, is characterized by
relatively larger GM volumes in several cortical areas, including the insula. LLD1 (positive
correlation) and LLD2 (negative correlation) are characterized by widespread patterns of
regional GM volumes, including the middle frontal gyrus, the insula, and the thalamus. For
schizophrenia, a widespread pattern of reduced brain volumes (e.g., insula) is associated with
SCZ1, whereas SCZ2 displays increased volumes of the putamen and pallidum. The details of
the P-value, sample sizes, and β values of the linear regression are presented in **Supplementary
eFile 1** (from disease-specific populations[1–4]) and **2** (from UKBB).
Compared to the disease populations, the neuroanatomical patterns of the nine DNEs
displayed remarkable deviations in the general population. These deviations were characterized
by significant over- and under-expression, except for ASD2, after correcting for multiple
comparisons using the Bonferroni method (**Fig. 2b**). For instance, AD1, characterized by diffuse
brain atrophy in the ADNI data, showed a significant under-expression (i.e., a smaller mean of
the DNE score) in the general population. Conversely, the subcortical atrophy pattern originally
identified in ASD1 from the ABIDE data displayed a significant over-expression (i.e., a larger
mean of the DNE score) in the participants from the general population.
These results provided compelling evidence that the nine DNEs are present in the general
population. The contrast in their expression (i.e., over- and under-expression) between the
disease-specific and UKBB general populations is expected and underscores their potential
relevance as sub-clinical or vulnerability quantitative indices.
170
171 **The nine DNEs exhibit phenotypic associations with traits beyond the brain**

172 To delineate their phenotypic landscape, we associated the nine DNEs with 611 phenotypes in
173 UKBB. To avoid circularity, the PWAS did not include the 119 GM ROIs derived from T1-

174 weighted MRI, from which the nine DNEs were derived. Out of the 611 additional clinical traits
175 spanning multiple organ systems, cognition, and lifestyle factors, we discovered 1818 significant
176 associations after applying the Bonferroni correction (P-value < 0.5/611) (**Fig. 2c**,
177 **Supplementary eFile 2**, and **Method 3c**).
178  Of the 1818 significant associations, 91% were related to the brain. For example, the
179 mean intracellular volume fraction in the superior frontal-occipital fasciculus derived from the
180 multi-shell NODDI[28] model was significantly associated with AD1 [β=-0.67±0.02, -$\log_{10}$(P-
181 value) > 300]. Multiple DNEs were significantly associated with the biological age gap (BAG:
182 AI-predicted age minus chronological age) of the brain [e.g., SCZ2: β=0.19±0.01, -$\log_{10}$(P-
183 value)=50.10]. Furthermore, 2% of the phenotypes related to the musculoskeletal system were
184 associated with the nine DNEs. The nine DNEs were also largely associated with many
185 phenotypes related to mental health (1%). For example, the neuroticism score was significantly
186 associated with LLD2 [β=-1.09x10^{-2}±2.42x10^{-3}, -$\log_{10}$(P-value)=5.20] (**Supplementary eFile 3**).
187  We conducted two sensitivity analyses to validate the main PWAS results (**Method 3c**).
188 We obtained high concordance rates in split-sample (98.03%) and sex-stratified analyses
189 (93.98%). Detailed results can be found in **Supplementary eText 1** and **Supplementary eFile 4**
190 and **5** for split-sample and sex-stratified analyses.
191  As anticipated, 91% of the significant associations were linked to the brain, given that the
192 DNEs were derived from regional brain volumetrics in brain disease-specific populations.
193 However, it is noteworthy that these phenotypic associations extended beyond the brain,
194 providing evidence for the significant associations between the brain and the rest of the body.

196 **Figure 2**: **Phenome-wide associations of the nine DNEs**

197
198 **a**) The neuroanatomical patterns of the nine DNEs were manifested in the UKBB general
199 population and were concordant with the patterns initially derived from the original disease
200 populations[1–4],. A linear regression model was applied to the 119 gray matter regions of interest
201 (ROIs) derived from T1-weighted MRI data while accounting for various covariates (**Method**
202 **3b**). We present the β coefficients of the ROIs that withstood the Bonferroni correction. Positive

correlations are depicted using warm reddish colors, while cold blue colors represent negative
correlations. For AD2, we showed the sagittal view to visualize the hippocampus and medial
temporal lobe. **b)** The nine DNEs are over-expressed (i.e., a higher mean of the DNE score in the
population) and under-expressed (i.e., a lower mean of the DNE score) in the general population
compared to the disease populations. The kernel density estimates of the nine DNEs are shown
for both the training dataset (gray-colored in patients) and the independent test dataset from the
UK Biobank (UKBB). Significant differences that survived the Bonferroni corrections between
the training and independent test datasets (two-sampled t-test) are denoted with the symbol *. **c)**
Phenome-wide associations (PWAS) between the nine DNEs (left panel) and 611 phenotypes
(middle panel) are dominated by brain phenotypic measures. The length of each rectangle block
indicates the percentage of associations for each DNE or phenotype category. The right panel
shows representative phenotypes linked to multiple phenotype categories with the highest
statistical significance after the Bonferroni correction (P-value<0.05/611). A thicker colored line
corresponds to a higher value of -log10(P-value). The symbols "+" and "-" represent positive and
negative correlations.

Genome-wide associations identify 66 genomic loci associated with the nine DNEs

At the genome-wide significance level (P-value<$5x10^{-8}$), GWAS (**Method 4a**) identified 10, 8,
5, 21, 9, 1, 3, 3, and 6 genomic loci significantly associated with AD1, AD2, ASD1, ASD2,
ASD3, LLD1, LLD2, SCZ1, and SCZ2, respectively (66 in total, **Fig. 3a,** and **Supplementary
eFile 6**). At a more stringent significance level (P-value<$5x10^{-8}/9$), 31 loci passed the Bonferroni
correction. Notably, 41 loci are novel – their top lead SNP was not associated with any clinical
traits in the EMBL-EBI GWAS Catalog[29], as annotated in **Fig. 3a (Method 4c**, query date: 2nd
June 2023, via FUMA version: v1.5.4**)**. To support the robustness of our GWAS, we estimated
the intercept of linkage disequilibrium score regression (LDSC)[30] and obtained intercepts of
1.003, 1.0314, 0.9969, 1.0155, 1.0129, 1.0131, 1.0166, 1.0109, 1.0127 for the nine DNEs. All
intercepts were close to 1, indicating no substantial genomic inflation in our GWASs. The
Manhattan and QQ plots of the nine GWASs are presented in **Supplementary eFigure 2-10**.
         All DNEs are significantly heritable ($0.24<h^2<0.66$, P-value<$1x10^{-10}$) after Bonferroni
correction (**Fig. 3a**, **Supplementary eTable 1**, and **Method 4b**). We employed the GCTA[31]
software to estimate h^2, acknowledging that previous research[32,33] has demonstrated variations in
the magnitude of h^2 estimates based on the choice of methods.
         We further investigated the significant genomic loci by mapping them to protein-
encoding genes and examining their functional implications through expression quantitative trait
loci (eQTL) mapping. **Supplementary eFigure 1** presents the regional Manhattan plot for the
most significant genomic locus associated with each DNE. For example, we identified a locus
associated with ASD2 (top lead SNP: rs3068507 at 20q11.21) and a neighboring locus associated
with SCZ1 (top lead SNP: rs6088962 at 20q11.21), both of which mapped to the *MYLK2* gene
(**Supplementary eFigure 1d** and **h**). *MYLK2* encodes a myosin light chain kinase primarily
expressed in adult skeletal muscle.
         We conducted six sensitivity analyses to validate the main GWAS results (**Method 4a**).
Overall, we obtained high concordance rates in split-sample, sex-stratified (63.26-92.54%), and
longitudinal GWAS analyses (100%, *N*=1116), but the concordance rates were relatively low in
non-European ancestry GWAS, independent ADNI GWAS, and six case-control GWAS[34–39] of
neurodegenerative and neuropsychiatric disorders from the psychiatric genetic consortium. Refer
to **Supplementary eText 2** and **Supplementary eTable 2** for details. The sample sizes for the

non-European (*N*=4783) and ADNI (*N*=1555) samples are small; the case-control GWAS from
the psychiatric genetic consortium may overlook the heterogeneity within each disease. Detailed
results are presented in **Supplementary eText 2** for the sensitivity results, **Supplementary eFile**
7-12 for replicated SNPs/loci, and **Supplementary eFigures 2-10** for Manhattan and QQ plots
and the LDSC intercepts. In addition, all GWAS results are also publicly available in the
MEDICINE web portal: http://labs.loni.usc.edu/medicine/. In conclusion, our GWASs identified
many novel genomic loci that previous case-control GWASs might have missed.
256
The genetic associations of the nine DNEs parallel their phenotypic associations

We performed a phenome-wide look-up analysis (**Method 4d**) to understand the phenotypic
associations of these identified genomic loci in the literature.
In total, 2525 clinical traits were associated with genetic variants in our GWAS,
including traits linked to multiple organ systems, cognition, and lifestyle factors (**Fig. 3b** and
Supplementary eFile 13). The genomic loci were largely associated with clinical traits of the
brain (53%), musculoskeletal (17%), immune system (6%), neurodegenerative (1%), and
neuropsychiatric (1%) diseases. For example, AD2 genomic loci were largely associated with
traits related to the brain (565 out of 781, e.g., IDPs), musculoskeletal (133/781, e.g., standing
height), immune (17/781, e.g., reticulocyte count), cognition (15/781, e.g., cognitive
performance), lifestyle factors (13/781, e.g., smoking), and neurodegenerative traits (1/781, i.e.,
neurofibrillary tangles).
The findings closely align with the phenotypic associations observed in **Fig. 2c**,
reinforcing that the DNEs share genetic determinants linked to organs beyond the brain, lifestyle
factors, and cognition.

Figure 3: **Genome-wide associations of the nine DNEs**

a) Genome-wide associations identified 66 (10, 8, 5, 21, 9, 1, 3, 3, 6 for the nine DNEs) genomic loci (P-value<5x10⁻⁸) associated with the nine DNEs. Using the top lead SNP, we denoted the 41 novel genomic loci – not associated with any clinical traits in the EMBL-EBI GWAS Catalog.

The left legend indicates the significant SNP-based heritability (h^2) for the nine DNEs; the right
legend represents the SNP density of our genetic data throughout the human genome. GWAS
was performed using the Genome Reference Consortium Human Build 37 (GRCh37). **b)**
Phenome-wide association query of the previously identified genomic loci (left panel) in the
EMBL-EBI GWAS Catalog (via FUMA 1.4.2) shows a brain-dominant genetic architecture. We
categorized all clinical traits (middle panel) into several high-level categories linked to multiple
organ systems, neurodegenerative and neuropsychiatric disorders, lifestyle factors, etc. We then
show the keyword cloud plots for each category (right panel).
285

The genetic correlation of the nine DNEs

To understand the shared genetic underpinnings, we estimated the genetic correlation[30] (g_c)
(**Method 4e**) between the nine DNEs, the BAG of nine human organ systems, and six brain
diseases (AD, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar,
obsessive-compulsive disorder, schizophrenia; **Supplementary eTable 2**) from the psychiatric
genetic consortium.
We first estimated the g_c between each pair of DNEs (**Fig. 4a**). Numerous DNEs
exhibited strong genetic correlations with each other. Among these, the highest positive genetic
correlation was obtained between ASD2 and SCZ1 (g_c=0.57±0.04); the highest negative genetic
correlations were obtained between ASD2 and ASD1 (g_c=-0.55±0.04), and between ASD3 and
SCZ1 (g_c=-0.51±0.05). We also observed a substantial alignment between the phenotypic
correlation (p_c) and the genetic correlation of pairwise DNEs, supporting the long-standing
Cheverud's Conjecture[40]. However, we identified two exceptions where the observed phenotypic
and genetic correlations exhibited opposite directions. ASD1 and ASD3 showed a negative
phenotypic (p_c=-0.39±0.08) but a positive genetic correlation (g_c=0.21±0.05); ASD1 and LLD1
showed a negative phenotypic (p_c=-0.34±0.09) but a positive genetic correlation (g_c=0.16±0.07)
(**Supplementary eTable 3**). This implies that non-genetic factors may exert opposite influences
on the two DNEs.
Between the nine DNEs and the BAGs across nine human organ systems, we found
significant genetic correlations between AD1 (g_c=0.23±0.05), ASD1 (g_c=0.44±0.05), LLD2
(g_c=0.24±0.07), SCZ1 (g_c=0.26±0.06), and the brain BAG, and between ASD1 and the eye BAG
(g_c=0.19±0.07) (**Fig. 4b** and **Supplementary eTable 4**).
Finally, we also found a marginally significant genetic correlation between AD2 and AD
(g_c=0.22±0.12), AD1 and bipolar disorder (BIP, g_c=-0.08±0.04), and ASD3 and BIP
(g_c=0.09±0.04) using GWAS summary statistics from the psychiatric genetic consortium (**Fig. 4c**
and **Supplementary eTable 5**).
In summary, the nine DNEs demonstrate substantial genetic correlations among
themselves and with organ systems beyond the brain, including the eye. These findings highlight
the interconnectedness of the neuroanatomical patterns and genetic determinants across multiple
body systems and diseases, suggesting shared underlying etiological factors and potential
pleiotropic effects.
317

318 **The genetic colocalization of the nine DNEs**

319 To seek the shared causal variants between two clinical traits (e.g., AD1 vs. LLD2), we
320 performed Approximate Bayes Factor colocalization[41] analyses (**Method 4f**) between the nine

DNEs (**Fig. 4d**), with the nine BAGs (**Fig. 4e**), and the six brain disorders from the psychiatric genetic consortium (**Fig. 4f**).

Among the nine DNEs, we detected 53 causal variants (SNPs) exhibiting significant colocalization signals. We showcased the shared causal variant (rs2790099 at 6p21.1) between ASD2 and SCZ2 with a PP.H4.ABF=0.92. This causal SNP was mapped to the *RUNX2* gene. The loss of function in *RUNX2* causes a rare autosomal dominant skeletal disorder – cleidocranial dysplasia[42], but it was implicated in ASD or SCZ in previous literature.

Between the nine DNEs and nine BAGs, we identified 16 causal variants (SNPs) exhibiting significant colocalization signals. We showcased the shared causal variant (rs5848503 at 3p22.1) between ASD2 and the brain BAG with a PP.H4.ABF=0.95. One mapped gene in this locus is the *MOPB* gene, which encodes the myelin-associated oligodendrocytes basic protein and is actively involved in the structural constituent of the myelin sheath and nervous system development. This gene was previously implicated in ASD using single-cell genomics[43], SCZ[44], amyotrophic lateral sclerosis, and Parkinson's disease[45].

Between the nine DNEs and six brain diseases from the psychiatric genetic consortium, we identified 7 causal variants (SNPs) exhibiting significant colocalization signals. We showcased the shared causal variant (rs9257566 at 6p22.1) between ASD3 and SCZ with a PP.H4.ABF=-0.82. In this locus, multiple olfactory receptor (OR) genes and the dysfunction of the olfactory system were implicated in SCZ[46,47] and ASD[48,49]. For instance, the *OR2J2* and *OR2J3* genes are two protein-coding genes in copy number variants associated with SCZ using microRNA data[50]. The causal SNP (rs9257566) was associated with SCZ and brain IDP, such as white matter microstructural measures (**Supplementary eFigure 11**). The sensitivity checks on the prior probability (*p12*) for the three illustrations are shown in **Supplementary eFigure 12a-c**. The causal variant, cytogenetic region, and their colocation signal direction (based on *β* coefficients) are presented in **Supplementary eFigure 13a-c** and **Supplementary eFile 14**, **15**, and **16**, respectively.

The genetic colocalization of the nine DNEs revealed causal genetic variants, indicating that the same genomic regions may causally influence the expression of these dimensional neuroimaging endophenotypes. The colocalization findings strengthen the notion that these DNEs share a fundamental genetic architecture.

The causal relationship of the nine DNEs

We applied bidirectional two-sample Mendelian randomization analyses[51] (**Method 4g**) to depict a causal network between the nine DNEs, the eight BAGs (excluding the brain BAG), and eleven chronic diseases spanning the whole-body system.

For each pair of DNEs, as the GWAS populations completely overlapped, conducting two-sample Mendelian randomization was not feasible[52]. Alternatively, the split-sample GWAS did not yield sufficient statistical power due to the limited number of instrumental variables (VI) available (< 6 SNPs).

Among the nine DNEs and eight BAGs, we found potential causal effects of the eye BAG on LLD1 [P-value=4.57×10^{-3}, OR (95% CI) = 1.14 (1.04, 1.24), number of SNPs=16], the cardiovascular BAG on ASD3 [P-value=6.04×10^{-3}, OR (95% CI) = 1.16 (1.04, 1.29), number of SNPs=34], and the pulmonary BAG on LLD2 [P-value=1.98×10^{-3}, OR (95% CI) = 1.14 (1.04, 1.25), number of SNPs=49]. No significant causal signals persisted after the Benjamini-Hochberg correction in the inverse analyses (**Fig. 4g**). Details of the results, including all five different Mendelian randomization estimators, are shown in **Supplementary eFile 17**.

Between the nine DNEs and eleven chronic diseases, encompassing brain-related
conditions and diseases affecting other organs, we identified a potential causal effect from AD2
to AD (but not the reversed direction) using the GWAS summary statistics from the psychiatric
genetic consortium – the largest sample size (N=1,126,536) in the AD case-control study [P-
value=1.74×10^{-4}, OR (95% CI) = 1.25 (1.11, 1.40), number of SNPs=7] (**Fig. 4h** and
Supplementary eFigure 17). Details of the results, including all five different Mendelian
randomization estimators, are shown in **Supplementary eFile 18**.
The Mendelian randomization results further emphasize the potential benefits of overall
organ health for brain-related conditions. This highlights the interconnectedness between various
organ systems and the brain, underscoring the significance of a holistic health and disease
prevention approach.

Figure 4: **The genetic correlation, colocalization, and causal networks of the nine DNEs**

a) The genetic correlation between two DNEs (g_c, lower triangle) mirrors their phenotypic
correlation (p_c, upper triangle). Red-shadowed rectangles highlight two exceptions. The symbol
* indicates significant results after the Benjamini-Hochberg correction. The symbol # indicates

nominal significance. **b**) genetic correlations between the nine DNEs and nine biological age
gaps (BAG) for nine human organ systems[17]. Solid arrow lines (from the exposure to the
outcome variables) indicate significant causal relationships after the Benjamini-Hochberg
correction; dotted arrow lines show nominal significance (P-value<0.05). **c**) genetic correlations
between the nine DNEs and six neurodegenerative and neuropsychiatric disorders. **d**) genetic
colocalization was evidenced at one locus (6p21.1) between ASD2 and SCZ1. The signed
PP.H4.ABF (0.92) denotes the posterior probability (PP) of hypothesis H4, which suggests that
both traits share the same causal SNP (rs2790099). A positive PP indicates concordant β values
for both DNEs, while a negative PP implies opposite β values. **e**) genetic colocalization was
evidenced at one locus (3p.22.1) between ASD2 and brain BAG: PP.H4.ABF=0.95 with the
cause SNP rs5848503. **f**) genetic colocalization was evidenced at one locus (6p.22.1) between
ASD3 and SCZ case-control GWAS[38] from the psychiatric genetic consortium (European
ancestry): PP.H4.ABF=-0.82 with the cause SNP rs9257566. **g**) the causal network of the nine
DNEs with the eight BAGs using bidirectional Mendelian randomization. **h**) the causal network
of the nine DNEs with the eleven chronic diseases (e.g., AD, ADHD, BIP, and SCZ from the
psychiatric genetic consortium). The symbols + (OR>1 and g_c>0) and – (OR<1 and g_c<0)
represent a positive relationship between the two traits. Abbreviation: AD: Alzheimer's disease;
ADHD: Attention-deficit/hyperactivity disorder; ASD: autism spectrum disorder; BIP: bipolar
disorder; SCZ: schizophrenia; OCD: Obsessive-compulsive disorder; RA: rheumatoid arthritis;
CD: Crohn's disease; T2D: type 2 diabetes; IBD: inflammatory bowel disease; PBC: Primary
biliary cirrhosis.
404
The nine DNEs and their PRSs significantly improve prediction for 14 systemic diseases

and mortality

We investigated the added prediction power of the nine DNEs and their respective PRS (**Method**
4h) for 14 systemic diseases based on the ICD-10 code and mortality outcomes (i.e., the date of
death). The definition of the patient and healthy control groups and the mortality outcome are
presented in **Method 5**. As anticipated, the prediction performance across all tasks was modest,
considering that the DNEs were derived from specific disease populations. However, the DNEs
can significantly enhance prediction performance when combined with other commonly
available features (e.g., age and sex).
In addition to commonly available features, such as age and sex, we found that AD1,
ASD1, LLD1, SCZ1, and SCZ2 provided additional prediction power (i.e., incremental R^2) for
many disease categories (**Method 5a**). Across the 14 disease categories, the DNEs showed
higher incremental R^2 in mental and behavioral disorders (ICD-10 code: F) and diseases linked to
the central nervous system (ICD-10 code: G) than other disease categories, proving that the nine
DNEs in the general population capture brain disease-related effects. Combining all nine DNEs
further improved the incremental R^2, especially in mental and behavioral disorders (R^2=1.01%,
P-value=1.74x10^{-5}) and diseases linked to the central nervous system (R^2=0.63%, P-
value=1.33x10^{-5}) (**Fig. 5a**). Detailed results are shown in **Supplementary eTable 6**. Results
using only the PRS target population are presented in **Supplementary eFigure 18**.
Compared to the nine DNEs, the nine PRSs provided smaller additional prediction power.
For example, the PRS for ASD3 explained an additional 0.05% of the variance (incremental R^2)
in diseases associated with the blood and immune systems (P-value=0.03), as well as neoplasms
(P-value=0.04). Combining all nine PRSs improves the incremental R^2, particularly in mental

and behavioral disorders (R^2=0.3%, P-value=0.047). No results survived the multiple
comparisons using the Benjamini-Hochberg method (**Fig. 5b**). Detailed results are shown in
Supplementary eTable 7.
We assessed the prediction ability of support vector machines (SVM) at the individual
level to classify the 14 disease categories (**Method 5b**). The highest performance was observed
for eye diseases (ICD-code: H0-5). The inclusion of PRSs, DNEs, and the combination of both,
along with age and sex as features, resulted in improved classification accuracy for mental and
behavioral disorders. For example, the accuracy increased from 0.51 to 0.55 and 0.57 for features
of age and sex, 9 DNESs, and 9 PRs, incrementally (**Fig. 5c**). These findings highlight the added
value of incorporating the nine DNEs and PRSs in predicting these disease categories. Detailed
results are shown in **Supplementary eTable 8**.
Finally, we evaluated the prediction power of the nine DNEs and PRSs for mortality risk
prediction using the Cox regression. Among these, SCZ1, SCZ1-PRS, ASD1, and AD1-PRS
were significantly associated with the risk of mortality (**Fig. 5d** and **Supplementary eTable 9a**).
Adding SCZ1, AD1-PRS, ASD1, and SCZ1-PRS to age and sex further improved the prediction,
but the performance decreased afterward (**Fig. 5e**). Lastly, incorporating the nine DNEs from the
second scan of 1348 participants into the model slightly increased the statistical significance and
the HR (**Supplementary eTable 9b** and **c**)

Figure 5: **Additional prediction power of the nine DNEs and PRSs for 14 systemic diseases and mortality outcomes**

a) The incremental R-squared (R^2) values of the nine DNEs for predicting 14 systemic disease categories were assessed using the entire UKBB sample, with N=39,178 participants as independent test data. The results focusing only on the PRS target population (N=15,891) can be found in **Supplementary eFigure 18**. The details to derive R^2 are presented in **Method 5a**. "ALL" indicates the incremental R^2 contributed by combining the nine DNEs. **b**) The incremental R^2 of the PRS of the nine DNEs to predict 14 systemic diseases based on the ICD-10 code using only the PRS target sample. **c**) In the PRS target sample, disease classification accuracy from the independently hold-out test data (N=5581) was assessed using nested cross-validated support vector machines in the training/validation/test data (N=10,000) by fitting various sets of features (Cov indicates age and sex). **d**) The SCZ1, SCZ1-PRS, AD1-PRS, and ASD1 show significant associations with the risk of mortality in the PRS target sample. Age and sex were included as covariates in the Cox proportional hazard model. **e**) The nine DNEs and PRSs were cumulatively

461   included as features in cross-validation for mortality risk prediction. The symbol * indicates
462   significant results that survived the Benjamini-Hochberg correction. The symbol # indicates
463   nominal significance. HR: hazard ratio; CI: concordance index.

Discussion

This study investigated the manifestation of nine disease-related brain endophenotypes – derived from four case-control studies via semi-supervised AI methods – in the general population of 39,178 participants in UKBB. We assessed commonalities and differences among the nine DNEs, their genetic correlates in the general population, their relationships with the multiple human organ systems, and their predictive capacity for 14 systemic disease categories and mortality. Our findings demonstrate the clinical applicability of the nine AI-derived DNEs in identifying high-risk individuals within the general population prone to developing the four major brain disorders.

Shared neuroanatomical patterns and genetic determinants across the four brain diseases

in the general population

Understanding the etiology of neurodegenerative and neuropsychiatric diseases is a complex and ongoing challenge in medical research[15,16,34,36–39,53]. Our results suggest that shared underlying mechanisms and genetic factors may contribute to these disorders' development and progression in the general population. This notion of shared etiology across the four major neurodegenerative and neuropsychiatric diseases, namely ASD, SCZ, LLD, and AD, has garnered considerable attention and reshapes our understanding of these conditions[15,16].

Despite the inherent heterogeneity among neuroanatomical patterns observed in different brain diseases (**Fig. 2a**), a notable commonality exists regarding their manifestations, which might emanate from underlying mechanisms sharing neuropathologic characteristics and pathways. As an illustration, AD1, LLD2, and SCZ1 exhibited a negative correlation (brain atrophy) with global cortical volume (e.g., bilateral insula and middle frontal gyrus). This aligns with expectations, considering that the UKBB population includes individuals primarily from mid to late life (above 45 years), evidenced by the brain chart of the human lifespan[54]. From an etiological standpoint, various factors can contribute to the global cortical volume reduction within the general population, with late-onset neurodegenerative and neuropsychiatric disorders and aging exerting a significant impact. Likewise, ASD2 and SCZ2 exhibited a positive association with the basal ganglia, including the globus pallidum. This could imply the existence of potential protective genetic or environmental factors that collectively contribute to the concept of "brain reserve", which might mitigate volume loss in a portion of the general population. Notably, we previously revealed that individuals predominantly expressing SCZ2 exhibited higher levels of education[4] and higher rates of remission compared to the group primarily influenced by SCZ1. Alternatively, these volume increases might reflect neuropathologic mechanisms, such as disrupted connectivity, which are not necessarily associated with neurodegenerative and neurodevelopmental components related to relatively lower brain volumes.

Overall, the commonalities in neuroanatomical patterns across brain diseases can be attributed to several factors. First, shared genetic factors may influence brain structure and function[26,55,56], contributing to similar neuroanatomical alterations across different diseases. For example, in one recent meta-analysis of 193 studies[57], the authors found a common brain network defined by positive connectivity to the anterior cingulate and insula and negative connectivity to the posterior parietal and lateral occipital cortex among six psychiatric disorders. Genetically, this was largely evidenced by our genetic correlation (**Fig. 4a**) and colocalization results (**Fig. 4d**). For instance, ASD2 showed prominent positive genetic overlap with SCZ1.

Historically, there has been a long-standing association between ASD and SCZ, leading to the
notion that autism could be a form of "childhood schizophrenia"[58]. This conceptual link between
the two conditions has been debated and discussed. Previous case-control neuroimaging studies
demonstrated divergent structural and functional brain patterns in individuals with ASD
compared to those with SCZ[59], largely ignoring the neuroanatomical heterogeneity within each
condition. Genetic variants that impact key signaling pathways, synaptic function, and neuronal
connectivity[60,61] could influence multiple disease phenotypes, leading to overlapping
neuroanatomical patterns. We performed additional MAGMA gene-set analysis[62] to test the
genetic similarity between ASD2 and SCZ1. The most significant biological pathway underlying
ASD2 is the negative regulation of locomotion (GO 0040013, P-value=2.27×10^{-5}, β=0.22±0.02),
implicated in biological processes that stop, prevent, or reduce the frequency, rate, or extent of
locomotion of a cell or organism. The most significant biological pathway for SCZ1 is the
negative regulation of neurotransmitter transport (GO 0051589, P-value=1.41×10^{-5},
β=0.22±0.02), involved in biological processes that downregulate the directed movement of a
neurotransmitter into, out of, or within a cell. In particular, the latter supports the involvement of
dopamine and glutamate, two major neurotransmitters in the central nervous system, in
schizophrenia[63], and the gross abnormalities of serotonin and dopamine transporter bindings in
autism patients[64].
AD1 also shared genetic similarities with LLD1, both characterized by spatially extensive
brain atrophy and increased brain age. Previous studies found a higher prevalence of depressive
symptoms and LLD in individuals with AD compared to the general population[65–67]. The
relationship between AD and LLD likely involves multiple factors and may be bidirectional. On
the one hand, LLD may increase the risk of developing AD or accelerate the progression of
cognitive decline in individuals already affected by AD. On the other hand, AD-related changes
in the brain, such as neuroinflammation and neurochemical imbalances, may worsen depressive
symptoms in individuals with LLD.
Recognizing the shared etiology across the four brain diseases challenges traditional
diagnostic boundaries and underscores the importance of a broader perspective on clinical
presentations and underlying biological mechanisms. This understanding is important for
developing targeted and personalized approaches to patient care, leading to more effective
treatments and interventions.
540
Beyond the brain

Our findings strongly concur with a paradigm shift in treating brain diseases. While the
conventional approach has predominantly concentrated on interventions targeting the brain,
emerging evidence highlights the critical importance of considering the broader systemic and
environmental factors that influence disease onset and progression[1,17,18,68,69].
Unraveling the intricate interconnections between the brain and other organ systems is
crucial in broadening our understanding of brain diseases, as demonstrated by our findings and
other findings[17,69]. The brain does not function in isolation but interacts with and is influenced by
various physiological systems throughout the body. Our results showed a close genetic
association and causality between the DNEs and the eye, cardiovascular, and pulmonary systems
(**Fig. 4b** and **g**). These findings parallel previous literature. For instance, eye-related pathological
changes have been revealed to mirror early signs of neurological and neuropsychiatric
conditions[70]. The nervous and cardiovascular systems – the heart-brain axis – are intricately
linked, with brain regions controlling heart function via sympathetic and parasympathetic

pathways[71]. Dysfunctions in one system can affect the other's function, resulting in brain and
cardiovascular diseases. The immune system plays a crucial role in modulating inflammation and
neuroinflammation, which are implicated in many brain disorders, such as AD[72], SCZ[73], and
depression[74]. Similarly, the gut-brain axis highlights the bidirectional communication between
the gut microbiota and the brain, with emerging evidence linking alterations in the gut
microbiome to brain diseases such as Parkinson's disease[75] and depression[76]. Understanding and
targeting these systemic interactions can modulate disease processes and improve treatment
outcomes.
Furthermore, considering environmental and lifestyle factors is essential in treating brain
diseases[77]. Our previous work[17] has shown that the BAGs of nine human organ systems comply
with Cheverud's Conjecture: the phenotypic correlation of two BAGs mirrors their genetic
correlations. However, herein we showed that the phenotypic correlation between two DNEs
(e.g., ASD1 vs. LLD1) did not reflect their underlying genetic correlation (**Fig. 4a**), indicating
potentially strong environmental and lifestyle factors that exert opposite effects on the two
DNEs. Furthermore, an interesting observation from our study was that the heritability estimate
(h^2) of early-onset diseases, such as ASD, was higher than that of late-onset diseases, such as
LLD, within the three neuropsychiatric disorders. This finding suggests that genetic factors play
a more prominent role in developing ASD at a younger age. In contrast, other factors, such as
environmental influences, socioeconomic factors, and lifestyle choices, may have a stronger
impact on developing LLD later in life. These differential heritability patterns shed light on the
complex interplay between genetic and non-genetic factors in the etiology of neurodegenerative
and neuropsychiatric disorders across different stages of life. These heritability patterns aligned
with a previous study that examined multiple GWAS drawn from more than 200,000 patients for
25 brain-associated disorders and 17 phenotypes[16].
In conclusion, going beyond the brain is crucial for understanding and treating brain
diseases. By considering the connections between the brain and other organ systems,
understanding the impact of environmental and lifestyle factors, and harnessing the power of
advanced AI technologies, we can develop more effective and personalized approaches to
prevent, diagnose, and treat brain diseases.
584
AI-derived DNEs for precision diagnostics in the general population

The present study leverages cutting-edge, semi-supervised AI methods[78] and open science
advancements to enhance our understanding of disease heterogeneity in neurodegenerative and
neuropsychiatric disorders[1–3,6,9]. In this context, implementing these AI-derived DNEs at early
disease or preclinical stages – in the general population – may facilitate the identification of
individuals at risk, and the initiation of proactive interventions before the onset of noticeable
symptoms, likely leading to more effective treatments and interventions and better outcomes.
The proposed AI-derived DNEs capture intricate brain structure and function variations,
often subtle and spatially complex, which traditional diagnostic methods and case-control studies
may overlook. By quantifying the neuroanatomical patterns associated with specific brain
disorders, DNEs may offer a personalized disease vulnerability assessment, inform interventions
at early preclinical stages, and potentially prevent or delay the onset of symptoms. At the
individual level, integrating genetic information (i.e., PRSs) with DNEs significantly improves
prediction performance for 14 systemic diseases and mortality outcomes (**Fig. 5**). In addition, our
Mendelian randomization analyses supported the well-established endophenotype hypothesis in
genetic psychiatry[21] – endophenotype in psychiatric disorders resides inside the causal pathway

from underlying genetics to their exo-phenotypes (i.e., the disease itself), thereby being closer to
its etiology. We found that AD2, characterized by focal medial temporal lobe atrophy, exerted a
causal relationship with AD. However, we did not find evidence of a reverse causal relationship,
suggesting that the underlying genetics may influence the development of AD through the DNE,
although it may not be the exclusive pathway contributing to the disease. This highlights the role
of genetics in influencing the disease process, particularly through the identified DNE, shedding
light on potential pathways and mechanisms involved in AD development.
The present study has several limitations. Firstly, the genetic analysis focused exclusively
on common genetic variants. Future investigations should explore the contribution of rare
variants to these brain diseases. Secondly, it is important to recognize that our GWAS analyses
predominantly involved participants of European ancestry, limiting the generalizability of the
genetic findings to other populations with different ancestral backgrounds. Further research
efforts are necessary to collect more diverse genetic data and include underrepresented ethnic
groups to enhance the generalizability of the findings. Additionally, the validation of the nine
DNEs would benefit from additional longitudinal analyses. Fortunately, ongoing efforts to
collect longitudinal brain MRI data in UKBB[79] hold promise for providing valuable insights to
the scientific community and advancing the field of precision medicine.
Together, our AI-derived DNEs have emerged as novel instruments for precision
medicine. By capturing the complexity and heterogeneity of brain disorders, DNEs provide a
better understanding of disease pathology, facilitate personalized risk assessment, and hold
promise for targeted interventions and population selection.

Methods

Method 1: Study populations

Our previous studies used semi-supervised AI models to define the nine DNEs from four disease case-control populations. These populations consisted of 865 healthy controls (CN), 1096 individuals with mild cognitive impairment (MCI), and 414 AD patients from ADNI[19], 362 typically developing controls and 307 patients with autism spectrum disorder (ASD) from ABIDE[20], 495 healthy controls and 501 LLD patients from the LLD study[3], and 364 healthy controls and 307 SCZ patients from PHENOM[4]. For more detailed information about the characteristics of the study populations, please refer to the original papers.

      The trained AI models were then applied to the UKBB general population as independent data. UKBB is a population-based study of approximately 500,000 people recruited between 2006 and 2010 from the United Kingdom. The UKBB study has ethical approval, and the ethics committee is detailed here: https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/governance/ethics-advisory-committee. The current study analyzed 39,178 multimodal brain MRI data from UKBB. T1-weighted MRI data were locally processed at the University of Pennsylvania; imaging-derived phenotypes (IDP) from diffusion and resting-state functional MRI were downloaded from UKBB. In addition, we processed the imputed genotype data[24] from UKBB for GWAS analyses. Last, other clinical traits were also analyzed, including phenotypes related to nine human organ systems[17,18]. The current work was performed under application numbers 35148 and 60698. To unbiasedly evaluate the PRS and machine learning models, we defined the following populations:

- *Disease case-control populations*: The four datasets used to train the AI models and define the nine DNEs from four brain diseases.
- *Independent UKBB general population (N=39,178)*: The UKBB population in which the trained AI models were applied to derive the nine DNEs.
- *PRS base/target population (split1/split2) (N=15,968)*: the UKBB population was divided into two splits (split1 vs. split2) in the split-sample GWAS. To derive the PRS, we used the GWAS from split1 as the base data and split2 as the target data. All disease and mortality prediction tasks involving PRS used only the PRS target population (*N*=15,968).

Method 2: Semi-supervised AI methods to derive the nine DNEs

The methodologies used in the current study to derive the nine DNEs belong to the semi-supervised learning algorithms (**Fig. 1a**) pioneered by our group. Refer to a review for details of this type of modeling[78]. In particular, the current study employed the HYDRA[27] and Surreal-GAN[14] models.

(a): HYDRA: HYDRA leverages a widely used discriminative method, i.e., support vector machines (SVM), to seek the "*1-to-k*" mapping. The novelty is that HYDRA extends multiple linear SVMs to the non-linear case piecewise, thereby simultaneously serving for classification and clustering. Specifically, it constructs a convex polytope by combining the hyperplane from *k* linear SVMs, separating the CN group from the *k* subpopulation of the PT (patient) group. Intuitively, each face of the convex polytope can be regarded to encode each subtype, capturing a distinct disease effect (**Supplementary eMethod 1a**).

(b): Surreal-GAN: Surreal-GAN[14] dissects underlying disease-related heterogeneity via a deep representation learning approach, instead of the discriminative SVM, under the principle of semi-supervised clustering – the "*1-to-k*" mapping. The methodological advance of this method is that Surreal-GAN models disease heterogeneity as a continuous dimensional representation, enforces monotone disease severity in each dimension, and allows the non-exclusive manifestation of all dimensions in the same participant (**Supplementary eMethod 1b**).

Method 3: Imaging analyses

(a): T1-weighted MRI processing: All images were first corrected for magnetic field intensity inhomogeneity.[80] A deep learning-based skull stripping algorithm was applied to remove extra-cranial material. In total, 145 IDPs were generated in gray matter (GM, 119 ROIs), white matter (WM, 20 ROIs), and ventricles (6 ROIs) using a multi-atlas label fusion method.[81] The ROIs were fit to the four machine learning models to derive the nine DNEs. The imaging quality check is detailed in **Supplementary eMethod 2**. The other IDPs derived from other MRI modalities (i.e., diffusion and resting-state MRI) were downloaded from UKBB.

(b): Neuroanatomical pattern of the nine DNEs: We assessed the neuroanatomical patterns exhibited by the nine DNEs within the general population. Since the DNEs were defined based on the 119 GM ROIs obtained from T1-weighted MRI scans, we aimed to test whether these patterns observed in the disease populations were manifested in the general population. To this end, we used a linear regression model in which each DNE was treated as the dependent variable, while the ROI, age, age-squared, sex, age x sex interaction, age-squared x sex interaction, intracranial volume, brain positions in the scan, and head motion were considered independent variables and covariates. We employed the Bonferroni method for multiple comparisons and reported significant results accordingly.

(c): PWAS for the nine DNEs: We performed PWAS to associate the nine DNEs to each of the 611 additional phenotypes (**Supplementary eFile 1**). PWAS excluded the 119 GM ROIs utilized to derive the nine DNEs to prevent any potential circular effects. Instead, the analysis incorporated IDPs from other modalities, such as diffusion and resting-state functional MRI. The same linear or logistic (for binary trait) regression models and multiple comparison corrections were employed.

　　To check the robustness of our PWAS results, we also performed two sensitivity checks: *i*) sex-stratified PWAS for males and females, and *ii*) split-sample PWAS by randomly dividing the entire population into two splits (sex and age did not significantly differ).

Method 4: Genetic analyses

We used the imputed genotype data for all genetic analyses, and our quality check pipeline resulted in 31,929 participants with European ancestry and 6,477,810 SNPs. First, we excluded related individuals (up to 2nd-degree) from the complete UKBB sample using the KING software for family relationship inference.[82] We then removed duplicated variants from all 22 autosomal chromosomes. Individuals whose genetically identified sex did not match their self-acknowledged sex were removed. Other excluding criteria were: i) individuals with more than

711   3% of missing genotypes; ii) variants with minor allele frequency (MAF) of less than 1%; iii)
712   variants with larger than 3% missing genotyping rate; iv) variants that failed the Hardy-
713   Weinberg test at 1×10^{-10}. To adjust for population stratification,[83] we derived the first 40 genetic
714   principle components (PC) using the FlashPCA software[84]. Details of the genetic quality check
715   protocol are described elsewhere[3,17,17,68].
716
(a): GWAS: For GWAS, we ran a linear regression using Plink[85] for each DNE, controlling for
confounders of age, age-squared, sex, age x sex interaction, age-squared x sex interaction, the
first 40 genetic principal components, total intracranial volume, three brain position parameters
in the scanner, and head motion were included, as suggested by a previous study[26]. We adopted
the genome-wide P-value threshold (5×10^{-8}) and annotated independent genetic signals
considering linkage disequilibrium (see below).
723   To check the robustness of our GWAS results, we also performed several sensitivity
checks: *i*) sex-stratified GWAS for males and females, *ii*) split-sample GWAS by randomly
dividing the entire population into two splits (sex and age did not significantly differ), *iii*)
comparison of the GWAS results using the 1348 participants (i.e., 1116 European ancestry) that
were collected for baseline and longitudinal scans from UKBB, *iv*) non-European GWAS
(N=4783), *v*) independent GWAS on ADNI whole-genome sequencing data (N=1555) on AD1
and AD2, *vi*) concordance with six European ancestry GWAS from the psychiatric genetic
consortium, including AD, ADHD, ASD, BIP, OCD, and SCZ (**Supplementary eTable 2**).
731
732   **(b): SNP-based heritability**: We estimated the SNP-based heritability (h^2) using GCTA[31] with
733   the same covariates as in GWAS.
734
(c): Annotation of genomic loci: The annotation of genomic loci and mapped genes was
performed via FUMA[86]. For the annotation of genomic loci, FUMA first defined lead SNPs
(correlation $r^2 \leq 0.1$, distance < 250 kilobases) and assigned them to a genomic locus (non-
overlapping); the lead SNP with the lowest P-value (i.e., the top lead SNP) was used to represent
the genomic locus. For gene mappings, three different strategies were considered. First, positional
mapping assigns the SNP to its physically nearby genes (a 10 kb window by default). Second,
eQTL mapping annotates SNPs to genes based on eQTL associations using the GTEx v8 data[87].
Finally, chromatin interaction mapping annotates SNPs to genes when there is a significant
chromatin interaction between the disease-associated regions and nearby or distant genes[86]. The
definition of top lead SNP, lead SNP, independent significant SNP, and candidate SNP can be
found in **Supplementary eMethod 3**.
746
747   **(d): Phenome-wide association queries for the identified loci in the GWAS Catalog**: We
748   queried the candidate and significant independent SNPs within each locus in the EMBL-EBI
749   GWAS Catalog (query date: 2nd June 2023, via FUMA version: v1.5.4) to determine their
750   previously identified associations with any other traits. For these associated traits, we further
751   mapped them into several high-level categories for visualization purposes.
752
(e): Genetic correlation: We used the LDSC[30] software to estimate the pairwise genetic
correlation (g_c) between each pair of DNEs, as well as between the nine DNEs and 9 BAGs of
multiple organ systems from our previous work[17] and 6 neurodegenerative and neuropsychiatric
disorders from the psychiatric genetic consortium (**Supplementary eTable 2**). We used the

precomputed LD scores from the 1000 Genomes of European ancestry. To ensure the suitability
of the GWAS summary statistics, we first checked that the selected study's population was
European ancestry; we then guaranteed a moderate SNP-based heritability h^2 estimate. Notably,
LDSC corrects for sample overlap and provides an unbiased estimate of genetic correlation[88].
Benjamini-Hochberg procedure was performed to account for multiple comparisons.
762
(f): Bayesian colocalization: We used the R package (*coloc*) to investigate the genetic
colocalization signals between two traits at each genomic locus. We employed the Fully
Bayesian colocalization analysis using Bayes Factors (*coloc.abf*). This method examines the
posterior probability (PP.H4.ABF: Approximate Bayes Factor) to evaluate hypothesis *H4*, which
suggests the presence of a single shared causal variant associated with both traits within a
specific genomic locus. To determine the significance of the *H4* hypothesis, we set a threshold of
PP.H4.ABF>0.8[41]. All other parameters (e.g., the prior probability of p_{12}) were set as default. We
also performed relevant sensitivity analyses to check the robustness of our findings.
771
(g): Two-sample bidirectional Mendelian randomization: We could not perform causal
inference between each pair of DNEs due to the overlapped populations and low sample sizes in
split-sample analyses.
We employed a bidirectional, two-sample Mendelian randomization using the
TwoSampleMR package[51] to infer the causal relationships between the nine DNEs and the eight
BAGs across nine human organ systems (excluding the brain). The forward and inverse
Mendelian randomization was performed between each trait pair by switching the exposure and
outcome variables. We applied five different Mendelian randomization methods and reported the
results of inverse variance weighted (IVW) in the main text and the four others (i.e., Egger,
weighted median, simple mode, and weighted mode estimators) in the supplement.
We then performed Mendelian randomization between the nine DNEs and eleven chronic
diseases spanning the whole-body system. These diseases include four diseases from the
psychiatric genetic consortium (the ASD and OCD GWAS summary statistics did not provide
the allele frequency information) and seven diseases unbiasedly curated in our previous work[17].
The included clinical traits in our Mendelian randomization are presented in **Supplementary**
eTable 10. Benjamini-Hochberg correction was performed for all tested traits.
We performed several sensitivity analyses. First, a heterogeneity test was performed to
check for violating the IV assumptions. Horizontal pleiotropy was estimated to navigate the
violation of the IV's exclusivity assumption[89] using a funnel plot, single-SNP Mendelian
randomization approaches, and Mendelian randomization Egger estimator[90]. Moreover, the
leave-one-out analysis excluded one instrument (SNP) at a time and assessed the sensitivity of
the results to individual SNP.
794
(h): PRS calculation for the nine DNEs: We calculated the PRS[91] using the GWAS results
from the split-sample analyses. The weights of the PRS were defined based on split1 data (base
data), and the split2 GWAS summary statistics were used as the target data for PRS calculation.
The QC steps for the base data are as follows: *i*) removal of duplicated and ambiguous SNPs for
the base data; *ii*) clumping the base GWAS data; *iii*) pruning to remove highly correlated SNPs
in the target data; *iv*) removal of high heterozygosity samples in the target data; *v*) removal of
duplicated, mismatching and ambiguous SNPs in the target data. After rigorous QC, we used
PLINK to generate PRS for the split2 population by adopting the classic C+T method (clumping

+ thresholding). To determine the "best-fit" PRS, we performed a linear regression using the PRS
calculated at different P-value thresholds (0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5), controlling for age,
sex, intracellular volume, and the first forty genetic PCs. For each DNE-PRS, we chose the P-
value threshold with the highest incremental R^2 (**Supplementary eFigure 19**).
807

Method 5: Disease and mortality outcome prediction.

We employed logistic regression to calculate the incremental R-squared (R^2) statistics of the nine
DNEs and PRSs to predict 14 disease categories (**a**), support vector machines to classify the
healthy control participants from the disease groups (**b**), and Cox proportional hazard model to
predict mortality outcomes (**c**). The patients for the 14 disease categories were defined based on
the ICD-10 code from the UKBB website: https://biobank.ndph.ox.ac.uk/ukb/field.cgi?id=40001.
The healthy control group included participants without any ICD-10-based disease diagnoses.
The mortality outcome refers to the date of death:
https://biobank.ndph.ox.ac.uk/ukb/field.cgi?id=40000.
817

(a): Pseudo R-squared (R^2) statistics of the logistic regression: We built a null model by
including age, sex, intracranial volume, brain positions in the scan, and head motion as predictors
and the disease as the outcome variable. The alternative model took the disease-specific DNE or
PRS as one additional predictor. The incremental R^2 was calculated as the difference between the
pseudo R^2 of the alternative model and that of the null model, implemented by the *PseudoR2*
function from the *DescTools* R package (v 0.99.38). For the nine PRSs, we used the PRS target
sample (N=15,891). For the nine DNEs, we calculated the incremental R^2 using the entire UKBB
sample (N=39,178) and the PRS target sample (N=15,891).
826

(b): Support vector machines to classify patients vs. controls: Using the PRS target sample
(N=15,891), we used 10000 participants in a nested cross-validation (CV) procedure (i.e., CV
training/validation/test datasets) to select the hyperparameter C in SVM. In addition, we held out
5581 participants as an independent test dataset. In **Fig. 5c**, we only presented the classification
accuracy from the independent test dataset. The nested cross-validation (CV) procedure[92]
involved an outer loop repeated 50 times, where 80% of the data was randomly selected for
training and 20% for testing. Within each outer loop iteration, an inner loop used 80% of the
training data for a 10-fold training/validation split.
835

(c): Cox proportional hazard model to predict the date of death: To evaluate the predictive
capacity of individual DNE and PRS for mortality risk, we employed a Cox proportional hazard
model while adjusting for covariates such as age and sex. The hazard ratio (HR) was calculated
and reported as the effect size measure that indicates the influence of each DNE or PRS on
mortality risk. Furthermore, we incrementally added the most predictive DNE or PRS to the Cox
model to determine when the model's performance reached saturation. The concordance index
(CI) was utilized to assess the model's performance using a 5-fold cross-validation procedure.
All survival analyses were conducted using the lifelines 0.25.7 Python package available online.

Data Availability

The GWAS summary statistics corresponding to this study are publicly available on the MEDICINE knowledge portal (https://labs.loni.usc.edu/medicine) and the FUMA online platform (https://fuma.ctglab.nl/).

Code Availability

The software and resources used in this study are all publicly available:
- MEDICINE: https://labs.loni.usc.edu/medicine, web portal for dissemination
- HYDRA: https://github.com/anbai106/mlni, DNEs for ASD1-3, LLD1-2, SCZ1-2
- Surreal-GAN: https://github.com/zhijian-yang/SurrealGAN, DNEs for AD1-2
- MLNI: https://github.com/anbai106/mlni, SVM classification
- PLINK: https://www.cog-genomics.org/plink/, GWAS, PRS
- FUMA: https://fuma.ctglab.nl/, gene mapping, genomic locus annotation
- GCTA: https://yanglab.westlake.edu.cn/software/gcta/#Overview, heritability estimates
- LDSC: https://github.com/bulik/ldsc, genetic correlation, partitioned heritability
- TwoSampleMR: https://mrcieu.github.io/TwoSampleMR/index.html, MR
- Coloc: https://chr1swallace.github.io/coloc/, Bayesian colocalization
- Lifelines: https://lifelines.readthedocs.io/en/latest/, Survival analyses

Competing Interests

None
863

Authors' contributions

Dr. Wen has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Wen

Acquisition, analysis, or interpretation of data: Wen

Drafting of the manuscript: Wen

Critical revision of the manuscript for important intellectual content: all authors

Statistical analysis: Wen

References

1. Wen, J. *et al.* Genetic, clinical underpinnings of subtle early brain change along Alzheimer's dimensions. 2022.09.16.508329 Preprint at https://doi.org/10.1101/2022.09.16.508329 (2022).

2. Hwang, G. *et al.* Assessment of Neuroanatomical Endophenotypes of Autism Spectrum Disorder and Association With Characteristics of Individuals With Schizophrenia and the General Population. *JAMA Psychiatry* (2023) doi:10.1001/jamapsychiatry.2023.0409.

3. Wen, J. *et al.* Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression. *JAMA Psychiatry* (2022) doi:10.1001/jamapsychiatry.2022.0020.

4. Chand, G. B. *et al.* Two distinct neuroanatomical subtypes of schizophrenia revealed using machine learning. *Brain* **143**, 1027–1038 (2020).

5. Young, A. L. *et al.* Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. *Nat Commun* **9**, 4273 (2018).

6. Yang, Z. *et al.* A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. *Nat Commun* **12**, 7065 (2021).

7. Zhang, X. *et al.* Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease. *Proc Natl Acad Sci USA* **113**, E6535–E6544 (2016).

8. Vogel, J. W. *et al.* Four distinct trajectories of tau deposition identified in Alzheimer's disease. *Nat Med* **27**, 871–881 (2021).

9. Wen, J. *et al.* Multi-scale semi-supervised clustering of brain images: Deriving disease subtypes. *Med Image Anal* **75**, 102304 (2021).

10. Ferreira, D., Nordberg, A. & Westman, E. Biological subtypes of Alzheimer disease: A

systematic review and meta-analysis. *Neurology* **94**, 436–448 (2020).

11. Hodson, R. Precision medicine. *Nature* **537**, S49–S49 (2016).

12. Davatzikos, C. *et al.* Precision diagnostics based on machine learning-derived imaging

signatures. *Magnetic Resonance Imaging* **64**, 49–61 (2019).

13. Leonenko, G. *et al.* Identifying individuals with high risk of Alzheimer's disease using

polygenic risk scores. *Nat Commun* **12**, 4506 (2021).

14. Yang, Z., Wen, J. & Davatzikos, C. Surreal-GAN:Semi-Supervised Representation

Learning via GAN for uncovering heterogeneous disease-related imaging patterns. *ICLR*

(2021).

15. Wingo, T. S. *et al.* Shared mechanisms across the major psychiatric and neurodegenerative

diseases. *Nat Commun* **13**, 4314 (2022).

16. Anttila, V. Analysis of shared heritability in common disorders of the brain. *Science* **360**,

eaap8757 (2018).

17. Wen, J. *et al.* The Genetic Architecture of Biological Age in Nine Human Organ Systems.

medRxiv 2023.06.08.23291168 (2023) doi:10.1101/2023.06.08.23291168.

18. Tian, Y. E. *et al.* Heterogeneous aging across multiple organ systems and prediction of

chronic disease and mortality. *Nat Med* 1–11 (2023) doi:10.1038/s41591-023-02296-6.

19. Petersen, R. C. *et al.* Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical

characterization. *Neurology* **74**, 201–209 (2010).

20. Di Martino, A. *et al.* Enhancing studies of the connectome in autism using the autism brain

imaging data exchange II. *Sci Data* **4**, 170010 (2017).

21. Kendler, K. & Neale, M. Endophenotype: a conceptual analysis. *Mol Psychiatry* **15**, 789–

797 (2010).

22. Cannon, T. D. & Keller, M. C. Endophenotypes in the Genetic Analyses of Mental

Disorders. *Annual Review of Clinical Psychology* **2**, 267–290 (2006).

23. Gottesman, I. I. & Gould, T. D. The endophenotype concept in psychiatry: etymology and

strategic intentions. *Am J Psychiatry* **160**, 636–645 (2003).

24. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

Nature **562**, 203–209 (2018).

25. Alfaro-Almagro, F. *et al.* Image processing and Quality Control for the first 10,000 brain

imaging datasets from UK Biobank. *Neuroimage* **166**, (2018).

26. Elliott, L. T. *et al.* Genome-wide association studies of brain imaging phenotypes in UK

Biobank. *Nature* **562**, 210–216 (2018).

27. Varol, E., Sotiras, A. & Davatzikos, C. HYDRA: Revealing heterogeneity of imaging and

genetic patterns through a multiple max-margin discriminative analysis framework.

NeuroImage **145**, 346–364 (2017).

28. Zhang, H., Schneider, T., Wheeler-Kingshott, C. A. & Alexander, D. C. NODDI: Practical

in vivo neurite orientation dispersion and density imaging of the human brain. *NeuroImage*

61, 1000–1016 (2012).

29. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association

studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* **47**, D1005–D1012

(2019).

30. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from

polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).

31. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: A Tool for Genome-wide
Complex Trait Analysis. *Am J Hum Genet* **88**, 76–82 (2011).

32. Speed, D., Holmes, J. & Balding, D. J. Evaluating and improving heritability models using
summary statistics. *Nat Genet* **52**, 458–462 (2020).

33. Evans, L. M. *et al.* Comparison of methods that use whole genome data to estimate the
heritability and genetic architecture of complex traits. *Nat Genet* **50**, 737–745 (2018).

34. Wightman, D. P. *et al.* A genome-wide association study with 1,126,563 individuals
identifies new risk loci for Alzheimer's disease. *Nat Genet* **53**, 1276–1282 (2021).

35. Demontis, D. *et al.* Genome-wide analyses of ADHD identify 27 risk loci, refine the
genetic architecture and implicate several cognitive domains. *Nat Genet* **55**, 198–208
(2023).

36. Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder.
Nat Genet **51**, 431–444 (2019).

37. Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder
cases provides new insights into the underlying biology. *Nat Genet* **53**, 817–829 (2021).

38. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in
schizophrenia. *Nature* **604**, 502–508 (2022).

39. International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-
GC) and OCD Collaborative Genetics Association Studies (OCGAS). Revealing the
complex genetic architecture of obsessive-compulsive disorder using meta-analysis. *Mol*
Psychiatry **23**, 1181–1188 (2018).

40. Cheverud, J. M. A COMPARISON OF GENETIC AND PHENOTYPIC
CORRELATIONS. *Evolution* **42**, 958–968 (1988).

41. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic

Association Studies Using Summary Statistics. *PLOS Genetics* **10**, e1004383 (2014).

42. Hordyjewska-Kowalczyk, E. *et al.* Functional analysis of novel RUNX2 mutations

identified in patients with cleidocranial dysplasia. *Clin Genet* **96**, 429–438 (2019).

43. Wamsley, B. *et al.* Molecular cascades and cell-type specific signatures in ASD revealed by

single cell genomics. 2023.03.10.530869 Preprint at

https://doi.org/10.1101/2023.03.10.530869 (2023).

44. Ayalew, M. *et al.* Convergent functional genomics of schizophrenia: from comprehensive

understanding to genetic risk prediction. *Mol Psychiatry* **17**, 887–905 (2012).

45. Siokas, V. *et al.* Myelin-associated oligodendrocyte basic protein rs616147 polymorphism

as a risk factor for Parkinson's disease. *Acta Neurologica Scandinavica* **145**, 223–228

(2022).

46. Arnold, S. E. *et al.* Dysregulation of olfactory receptor neuron lineage in schizophrenia.

Arch Gen Psychiatry **58**, 829–835 (2001).

47. Turetsky, B. I., Moberg, P. J., Arnold, S. E., Doty, R. L. & Gur, R. E. Low olfactory bulb

volume in first-degree relatives of patients with schizophrenia. *Am J Psychiatry* **160**, 703–

708 (2003).

48. Almandil, N. B. *et al.* Exome-wide analysis identify multiple variations in olfactory

receptor genes (OR12D2 and OR5V1) associated with autism spectrum disorder in Saudi

females. *Frontiers in Medicine* **10**, (2023).

49. Kuo, P.-H. *et al.* Genome-Wide Association Study for Autism Spectrum Disorder in

Taiwanese Han Population. *PLOS ONE* **10**, e0138695 (2015).

50.   Warnica, W. *et al.* Copy number variable microRNAs in schizophrenia and their

985   neurodevelopmental gene targets. *Biol Psychiatry* **77**, 158–166 (2015).

986   51.   Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the

987   human phenome. *eLife* **7**, e34408 (2018).

988   52.   Sanderson, E. *et al.* Mendelian randomization. *Nat Rev Methods Primers* **2**, 1–21 (2022).

989   53.   23andMe Research Team *et al.* Genome-wide association study of depression phenotypes

990   in UK Biobank identifies variants in excitatory synaptic pathways. *Nat Commun* **9**, 1470

991   (2018).

992   54.   Bethlehem, R. a. I. *et al. Brain charts for the human lifespan*. 2021.06.08.447489

993   https://www.biorxiv.org/content/10.1101/2021.06.08.447489v1 (2021)

994   doi:10.1101/2021.06.08.447489.

995   55.   Wen, J. *et al.* Novel genomic loci and pathways influence patterns of structural covariance

996   in the human brain. 2022.07.20.22277727 Preprint at

997   https://doi.org/10.1101/2022.07.20.22277727 (2022).

998   56.   Zhao, B. *et al.* Genome-wide association analysis of 19,629 individuals identifies variants

999   influencing regional brain volumes and refines their genetic co-architecture with cognitive

1000   and mental health traits. *Nat Genet* **51**, 1637–1644 (2019).

1001   57.   Taylor, J. J. *et al.* A transdiagnostic network for psychiatric illness derived from atrophy

1002   and lesions. *Nat Hum Behav* **7**, 420–429 (2023).

1003   58.   Zeldovich, L. Cold parenting? Childhood schizophrenia? How the diagnosis of autism has

1004   evolved over time. *Science* doi: 10.1126/science.aau1206 (2018).

1005   59.   Moreau, C. A. *et al.* Dissecting autism and schizophrenia through neuroimaging genomics.

1006   *Brain* **144**, 1943–1957 (2021).

60.   Bereczki, E. *et al.* Synaptic markers of cognitive decline in neurodegenerative diseases: a

proteomic approach. *Brain* **141**, 582–595 (2018).

61.   Jiang, C.-C. *et al.* Signalling pathways in autism spectrum disorder: mechanisms and

therapeutic implications. *Sig Transduct Target Ther* **7**, 1–36 (2022).

62.   Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-

Set Analysis of GWAS Data. *PLOS Computational Biology* **11**, e1004219 (2015).

63.   McCutcheon, R. A., Krystal, J. H. & Howes, O. D. Dopamine and glutamate in

schizophrenia: biology, symptoms and treatment. *World Psychiatry* **19**, 15–33 (2020).

64.   Nakamura, K. *et al.* Brain Serotonin and Dopamine Transporter Bindings in Adults With

High-Functioning Autism. *Archives of General Psychiatry* **67**, 59–68 (2010).

65.   Chi, S., Yu, J.-T., Tan, M.-S. & Tan, L. Depression in Alzheimer's disease: epidemiology,

mechanisms, and management. *J Alzheimers Dis* **42**, 739–755 (2014).

66.   Dafsari, F. S. & Jessen, F. Depression—an underrecognized target for prevention of

dementia in Alzheimer's disease. *Transl Psychiatry* **10**, 1–13 (2020).

67.   Ly, M. *et al.* Late-life depression and increased risk of dementia: a longitudinal cohort

study. *Transl Psychiatry* **11**, 1–10 (2021).

68.   Wen, J. *et al.* The Genetic Heterogeneity of Multimodal Human Brain Age. *bioRxiv*

2023.04.13.536818 (2023) doi:10.1101/2023.04.13.536818.

69.   Zhao, B. *et al.* Heart-brain connections: Phenotypic and genetic insights from magnetic

resonance images. *Science* **380**, abn6598 (2023).

70.   Woo, M. Eyes hint at hidden mental-health conditions. *Eyes hint at hidden mental-health*

conditions https://www.nature.com/articles/d41586-019-01114-9 (2019).

71.   Tahsili-Fahadan, P. & Geocadin, R. G. Heart–Brain Axis. *Circulation Research* **120**, 559–

572 (2017).

72.   Leng, F. & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease:

where do we go from here? *Nat Rev Neurol* **17**, 157–172 (2021).

73.   Murphy, C. E., Walker, A. K. & Weickert, C. S. Neuroinflammation in schizophrenia: the

role of nuclear factor kappa B. *Transl Psychiatry* **11**, 1–13 (2021).

74.   Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary

imperative to modern treatment target. *Nat Rev Immunol* **16**, 22–34 (2016).

75.   Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome–gut–brain axis in Parkinson disease

— from basic research to the clinic. *Nat Rev Neurol* **18**, 476–495 (2022).

76.   Morais, L. H., Schreiber, H. L. & Mazmanian, S. K. The gut microbiota–brain axis in

behaviour and brain disorders. *Nat Rev Microbiol* **19**, 241–255 (2021).

77.   Tost, H., Champagne, F. A. & Meyer-Lindenberg, A. Environmental influence in the brain,

human welfare and mental health. *Nat Neurosci* **18**, 1421–1431 (2015).

78.   Wen, J. *et al.* Subtyping brain diseases from imaging data. Preprint at

https://doi.org/10.48550/arXiv.2202.10945 (2022).

79.   UKBB, U. Ambitious project announced to create the world's largest longitudinal imaging

dataset. https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/ambitious-

project-announced-to-create-the-world-s-largest-longitudinal-imaging-dataset.

80.   Tustison, N. J. *et al.* N4ITK: improved N3 bias correction. *IEEE Trans. Med. Imaging* **29**,

1310–1320 (2010).

81.   Doshi, J. *et al.* MUSE: MUlti-atlas region Segmentation utilizing Ensembles of registration

1051   algorithms and parameters, and locally optimal atlas selection. *Neuroimage* **127**, 186–195

1052   (2016).

1053   82.   Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.

1054   *Bioinformatics* **26**, 2867–2873 (2010).

1055   83.   Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population

1056   stratification in genome-wide association studies. *Nat Rev Genet* **11**, 459–463 (2010).

1057   84.   Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-

1058   scale genotype datasets. *Bioinformatics* **33**, 2776–2778 (2017).

1059   85.   Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based

1060   Linkage Analyses. *Am J Hum Genet* **81**, 559–575 (2007).

1061   86.   Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and

1062   annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).

1063   87.   The GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**,

1064   580–585 (2013).

1065   88.   Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.

1066   *Nat Genet* **47**, 1236–1241 (2015).

1067   89.   Bowden, J. *et al.* A framework for the investigation of pleiotropy in two-sample summary

1068   data Mendelian randomization. *Stat Med* **36**, 1783–1802 (2017).

1069   90.   Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid

1070   instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*

1071   **44**, 512–525 (2015).

1072   91.   Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk

1073   score analyses. *Nat Protoc* **15**, 2759–2772 (2020).

1074   92.   Wen, J. *et al.* Convolutional neural networks for classification of Alzheimer's disease:

1075   Overview and reproducible evaluation. *Medical Image Analysis* **63**, 101694 (2020).

1076

1077

Acknowledgments

We want to express our sincere gratitude to the UK Biobank team for their invaluable contribution to advancing clinical research in our field. We extend our gratitude to the psychiatric genetic consortium (PGC: https://pgc.unc.edu/) for their generosity in sharing the GWAS summary statistics with the broader scientific community. This study used the UK Biobank resource under Application Numbers: 35148 and 60698. Additionally, we extend our appreciation to the psychiatric genetic consortium for their valuable contribution to sharing the GWAS summary statistics with the scientific community. Lastly, we acknowledge the collaboration between the University of Southern California, the University of Pennsylvania, and the University of Melbourne in conducting this research. We gratefully acknowledge the support of the iSTAGING consortium, funded by the National Institute on Aging through grant RF1 AG054409 at the University of Pennsylvania (CD). We also acknowledge the funding provided by the National Institute of Biomedical Imaging and Bioengineering at the University of Southern California through grant 5P41EB015922-25 (AT). Additionally, we acknowledge the funding program from the Rebecca L. Cooper Foundation at the University of Melbourne (AZ).